Prot. CCFZ533A2201: A 12 month, partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody, CFZ533, in de novo and mainte

Project: Research project

StatusActive
Effective start/end date1/15/205/12/26

Funding

  • Novartis Pharmaceuticals Corporation (Prot. CCFZ533A2201)